Table of Contents
National Fall SBIR/STTR Conference
A Word About Genaissance
Our Mission
How Does HAP™ Technology Work?
How Does HAP™ Technology Work?
DNA Markers Coupled to Drugs:.A Means of Targeted Therapy.
Intellectual Property and Value Chain
Pharmacogenetics for drug development
Money Raised
PPT Slide
Corporate Taglines
Introduction to Pharmacogenetics
Beyond Pharmacodynamics and Pharmacokinetics
Beyond Pharmacodynamics and Pharmacokinetics
HAP™ Markers
HAP™ Database as of September 6, 2002.All key pharmaceutical genes
Most detailed examination of.variability in human genes
Effects of Gene Variability on Drug Response
Clinical Pharmacogenetic Studies
Connecting HAP™ Markers to Breathing Improvement
Clinical Pharmacogenetic Studies
HAP™ Marker Associations Discovered. (as of September 2002)
Towards a Genetic Structure of Statins
National Cholesterol Education Program.Adult Treatment Panel III (ATP III) Guidelines
A Randomized, Open-Label Investigation of Drug Response in Relationship to Gene Variants (HAP™ Markers) in Adult Subjects with Primary Hypercholesterolemia
Conclusions
The Future of Personalized Medicines
Drivers for Personalized Medicine
PPT Slide
PPT Slide
Product Safety
Product Personalization
Balancing Foresight and Reality
Genaissance Current Partnerships
Revenue History
Prescribing HAP™ Drugs
Prescribing HAP™ Drugs
From Genotype to Phenotype
PPT Slide
Genaissance and the SBIR Program
Phase II Grants
Grants That Were Instrumental In Genaissance’s Development
SBIR Funding by Year
SBIR Funding as a Percentage of.Total Revenue
From DNA .to Drugs to Drug Response
|
Author: Gualberto Ruano, M.D., Ph.D.
Download PowerPoint Presentation Source (PPT)
(Note: This is a 12MB file)
|